By |

Profile

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and Stendra/Spedra, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. The company operates through the single segment of business being Development and commercialization of novel therapeutic products.

Contact Information

Website: www.vivus.com
Email: oki@vivus.com
Main Phone: +1 650 934-5200
Address: 900 East Hamilton Avenue
Address 2: Suite 550
State: CA
City / Town: Campbell
Country: USA
Postal Code: 95008

Issuer Information

Exchange: NGS
CEO: John Amos
Employees: 57
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and Stendra/Spedra, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. The company operates through the single segment of business being Development and commercialization of novel therapeutic products.

Contact Information

Website: www.vivus.com
Email: oki@vivus.com
Main Phone: +1 650 934-5200
Address: 900 East Hamilton Avenue
Address 2: Suite 550
State: CA
City / Town: Campbell
Country: USA
Postal Code: 95008

Issuer Information

Exchange: NGS
CEO: John Amos
Employees: 57
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 3.98 $ 0.03 (0.76%)
Last Price 3.98 Change $ 0.03 Change % 0.76 Tick N/A
Bid 3.90 Bid Size 1,200.00 Ask 4.00 Ask Size 200.00
Open 4.00 High 4.16 Low 3.77 Prev Close 3.95
Last Trade Volume 149,818 52 Wk Hi 6.41 52 Wk Low 2.15
Market Cap 42.4 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 10,642,713.00 EPS (TTM) -2.60 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 21 84
Number of Buys 14 42
Number of Sells 7 42
Net Activity 1986296 2081173
Last 10 Buys Shares
Herm Rosenman 1,000
Herm Rosenman 1,000
Herm Rosenman 1,000
John Amos 1,000
John Amos 1,000
John Amos 1,000
John Amos 1,000
John Amos 1,000
John Amos 1,000
Conan Laughlin 1,000
Last 10 Sell Shares
John Amos 1,000
Santosh T Varghese 1,000
Santosh T Varghese 1,000
Santosh T Varghese 1,000
Santosh T Varghese 1,000
Santosh T Varghese 1,000
Santosh T Varghese 1,000
Conan Laughlin 1,000
Conan Laughlin 1,000
Conan Laughlin 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 1.5 1.5 1.5 1.5
Low Target Price Estimate 1.5 1.5 1.5 1.5
Mean Target Price Estimate 1.5 1.5 1.5 1.5
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 05/08/18 05/08/18 05/08/18 05/08/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3 3 3 3